L Wallentin

Summary

Affiliation: Uppsala University Hospital
Country: Sweden

Publications

  1. Wallentin L, Hijazi Z, Andersson U, Alexander J, De Caterina R, Hanna M, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARIS. Circulation. 2014;130:1847-58 pubmed publisher
    ..The prognostic value for major bleeding and death remained even in the presence of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin I. http://www.clinicaltrials.gov. Unique identifier: NCT00412984. ..
  2. Wallentin L, Lopes R, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127:2166-76 pubmed publisher
    ..The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers' and patients' predicted quality of international normalized ratio control. ..
  3. Velders M, Wallentin L, Becker R, van Boven A, Himmelmann A, Husted S, et al. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. Am Heart J. 2015;169:879-889.e7 pubmed publisher
    ..Biomarker measurement on admission is feasible and provides incremental risk stratification in patients with STEMI treated with PPCI, with NT-proBNP and GDF-15 being most valuable due to the association with both CVD and spontaneous MI. ..
  4. Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57 pubmed publisher
    ..ClinicalTrials.gov number, NCT00391872.) ..
  5. Wallentin L, Held C, Armstrong P, Cannon C, Davies R, Granger C, et al. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016;5: pubmed publisher
    ..URL: https://www.clinicaltrials.gov. Unique identifier: NCT00799903. ..
  6. Wallentin L, Lindhagen L, Ärnström E, Husted S, Janzon M, Johnsen S, et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016;388:1903-1911 pubmed publisher
    ..Swedish Heart-Lung Foundation, Swedish Foundation for Strategic Research, and Uppsala Clinical Research Center. ..
  7. Wallentin L, James S, Storey R, Armstrong M, Barratt B, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320-8 pubmed publisher
    ..Use of ticagrelor instead of clopidogrel eliminates the need for presently recommended genetic testing before dual antiplatelet treatment. AstraZeneca. ..